ClearPoint Neuro reports Q4 revenue $4.3M (+15%) and record 2021 revenue $16.3M (+27%)

ClearPoint Neuro, Inc.

2022-FY EPS reported -$0.69 revenue$16,299,000

Q4 2021 revenue $4.3M (+15% YoY); full-year revenue $16.3M (+27% YoY), seventh consecutive year of growth.
Biologics & drug delivery revenue $6.8M in 2021 (+31% YoY); supported 929 cases despite COVID.
Cash and equivalents $54.1M at year-end, up from $20.1M, aided by Feb 2021 public offering raising ~$46.8M net.
Operating expenses increased to $24.7M (2021) from $15.3M (2020) due to headcount and R&D investments.
2022 revenue guidance reaffirmed at $20-22M; progress on pillars including FDA clearance for Array and BCI collab.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.